PL3906934T3 - Zastosowanie Dalarginu w zapobieganiu wirusowym infekcjom dróg oddechowych i zapobieganiu rozwojowi powikłań podczas wirusowych infekcji dróg oddechowych - Google Patents

Zastosowanie Dalarginu w zapobieganiu wirusowym infekcjom dróg oddechowych i zapobieganiu rozwojowi powikłań podczas wirusowych infekcji dróg oddechowych

Info

Publication number
PL3906934T3
PL3906934T3 PL20173355.7T PL20173355T PL3906934T3 PL 3906934 T3 PL3906934 T3 PL 3906934T3 PL 20173355 T PL20173355 T PL 20173355T PL 3906934 T3 PL3906934 T3 PL 3906934T3
Authority
PL
Poland
Prior art keywords
viral infections
respiratory viral
dalargin
prevention
development
Prior art date
Application number
PL20173355.7T
Other languages
English (en)
Inventor
Evgeny Alexandrovich Chertorizhsky
Vyacheslav Stanislavovich KOSORUKOV
Aleksey Viktorovich Kleimenov
Gennady Dmitrievich MELNIKOV
Original Assignee
Pvp Labs Pte. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pvp Labs Pte. Ltd. filed Critical Pvp Labs Pte. Ltd.
Publication of PL3906934T3 publication Critical patent/PL3906934T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL20173355.7T 2020-05-06 2020-05-06 Zastosowanie Dalarginu w zapobieganiu wirusowym infekcjom dróg oddechowych i zapobieganiu rozwojowi powikłań podczas wirusowych infekcji dróg oddechowych PL3906934T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20173355.7A EP3906934B1 (en) 2020-05-06 2020-05-06 Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections

Publications (1)

Publication Number Publication Date
PL3906934T3 true PL3906934T3 (pl) 2025-02-24

Family

ID=70613705

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20173355.7T PL3906934T3 (pl) 2020-05-06 2020-05-06 Zastosowanie Dalarginu w zapobieganiu wirusowym infekcjom dróg oddechowych i zapobieganiu rozwojowi powikłań podczas wirusowych infekcji dróg oddechowych

Country Status (8)

Country Link
US (1) US20210346459A1 (pl)
EP (1) EP3906934B1 (pl)
EA (1) EA202192687A1 (pl)
ES (1) ES3002532T3 (pl)
HU (1) HUE069345T2 (pl)
PL (1) PL3906934T3 (pl)
RS (1) RS66259B1 (pl)
WO (1) WO2021224664A1 (pl)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1475670A1 (ru) * 1986-03-24 1989-04-30 В.А.Виноградов, М.И.Титов, Н.П.Буглак и Н.Н.Богданов Способ лечени звенной болезни двенадцатиперстной кишки
US8232320B2 (en) * 1999-04-28 2012-07-31 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
IT1400067B1 (it) * 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
RU2436588C1 (ru) * 2010-07-06 2011-12-20 Общество с ограниченной ответственностью "Биофарм" Даларгинсодержащая интраназальная композиция и ее применение для лечения заболеваний
CN102370673A (zh) * 2010-08-23 2012-03-14 王登之 苏冰(速效救心)喷雾剂及其制备方法
CA3011015C (en) * 2016-01-12 2024-04-16 Nortic Holdings Inc. Betamethasone oral spray formulation and method of use to treat ataxia
RU2672888C1 (ru) * 2018-04-18 2018-11-20 Пивипи Лабс Пте. Лтд. Противовирусное иммунотропное средство для лечения ОРВИ

Also Published As

Publication number Publication date
EP3906934A1 (en) 2021-11-10
ES3002532T3 (en) 2025-03-07
RS66259B1 (sr) 2024-12-31
WO2021224664A1 (en) 2021-11-11
HUE069345T2 (hu) 2025-03-28
US20210346459A1 (en) 2021-11-11
EP3906934B1 (en) 2024-09-25
EA202192687A1 (ru) 2022-02-09

Similar Documents

Publication Publication Date Title
PL3556377T3 (pl) Dalargin do stosowania w leczeniu ostrych infekcji wirusowych dróg oddechowych
IL289975A (en) Use of cannabidiol in the treatment of dravet syndrome
EP4466269A4 (en) PARP1 INHIBITORS AND THEIR USES
SI3759083T1 (sl) Derivati 2,4-diaminokinazolina in njihova uporaba v zdravljenju virusnih okužb, raka ali alergij
EP4003355A4 (en) DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE
EP4117704A4 (en) Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
PL3823623T3 (pl) Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemu
ITUB20160543A1 (it) Composizione oftalmica stabilizzante e reintegrante del film lacrimale per uso nella prevenzione delle infezioni virali
EP3790866A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
KR20240101563A9 (ko) 쇼그렌 증후군의 치료 및 예방을 위한 cd40l-특이적 tn3-유래된 스캐폴드
GB2607709B (en) Lens sets for use in preventing or slowing the development or progression of myopia and related methods
IL309355A (en) Compositions and their use for the treatment of α1-antitrypsin deficiency
HUE069345T2 (hu) Dalargin alkalmazása vírusos légúti fertõzések megelõzésére és szövõdményeik kialakulásának megelõzésére vírusos légúti fertõzések során
EP4003987A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
PT3937949T (pt) Fitoecdisonas e seus derivados para utilização no tratamento da alteração da função respiratória
GB202103578D0 (en) Prevention and treatment of infections including those caused by coronavirus
LT4110288T (lt) Vietinė kompozicija, skirta palaikyti ir (arba) atkurti gleivinės ir pažeisto epidermio vientisumą
IT201700034630A1 (it) Pad2 per uso nella prevenzione e/o trattamento o diagnosi di infezioni da virus della famiglia herpesviridae
ES3066501T3 (en) Methods and pharmaceutical compositions for treating and preventing acute respiratory distress syndrome associated with viral infections
HUE060482T2 (hu) Parapoxvírus koronavírus fertõzések kondícionálására és kezelésére
PL3999069T3 (pl) Synergistyczne działanie eyp001 i pegylowanego ifn-alfa w leczeniu zakażenia hbv
JP1737997S (ja) ゲーム用ラケット
JP1737996S (ja) ゲーム用ラケット
EP4003997A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
HK40085151A (en) Sars-cov2-specific t cell compositions and their use in treating and preventing coronavirus and other respiratory virus infections